Marquette University

e-Publications@Marquette
Mathematics, Statistics and Computer Science
Faculty Research and Publications

Mathematics, Statistics and Computer Science,
Department of

4-1-2017

Deriving a Provisional Tolerable Intake for
Intravenous Exposure to Silver Nanoparticles
Released from Medical Devices
Laura C. Savery
U.S. Food and Drug Administration

Rene Vinas
U.S. Food and Drug Administration

Amber M. Nagy
U.S. Food and Drug Administration

Prachi Pradeep
Marquette University, prachi.pradeep@marquette.edu

Stephen Merrill
Marquette University, stephen.merrill@marquette.edu
See next page for additional authors

Accepted version. Regulatory Toxicology and Pharmacology, Vol. 85 (April 2017): 108-118. DOI. ©
2018 Elsevier B.V. Used with permission.

Authors

Laura C. Savery, Rene Vinas, Amber M. Nagy, Prachi Pradeep, Stephen Merrill, Subhas G. Malghan, Peter L.
Goering, and Ronald P. Brown

This article is available at e-Publications@Marquette: https://epublications.marquette.edu/mscs_fac/556

Marquette University

e-Publications@Marquette
Mathematics, Statistics and Computer Science Faculty Research and
Publications/College of Arts and Sciences
This paper is NOT THE PUBLISHED VERSION; but the author’s final, peer-reviewed manuscript. The
published version may be accessed by following the link in the citation below.

Regulatory Toxicology and Pharmacology, Vol. 85 (April, 2017): 108-118. DOI. This article is © Elsevier
and permission has been granted for this version to appear in e-Publications@Marquette. Elsevier
does not grant permission for this article to be further copied/distributed or hosted elsewhere without
the express permission from Elsevier.

Deriving a Provisional Tolerable Intake for Intravenous
Exposure to Silver Nanoparticles Released from Medical
Devices
Laura C. Savery
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring,
MD

René Viñas
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring,
MD

Amber M. Nagy
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring,
MD

Prachi Pradeep
Department of Mathematics, Statistics, and Computer Science, Marquette University,
Milwaukee, WI

Stephen J. Merrill
Department of Mathematics, Statistics, and Computer Science, Marquette University,
Milwaukee, WI

Alan M. Hood
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring,
MD

Subhas G. Malghan
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring,
MD

Peter L. Goering
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring,
MD

Ronald P. Brown
Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring,
MD

Highlights
• Provisional tolerable intake value was derived for intravenous exposure to
nanoparticles released from medical devices.
• Critical study selection was based on the Annapolis Accords principles and
Toxicological Data Reliability Assessment Tool.
• Modifying factor of 1,000 was determined by scientific review and analysis accounting
for uncertainties.
• Provisional tolerable intake for i. v. exposure to silver nanoparticles was calculated to
be 0.14 µg/kg bw/day.
• Methodology presented is appropriate for deriving provisional tolerable intake value for
nanoparticles in general.

Abstract
Silver nanoparticles (AgNP) are incorporated into medical devices for their anti-microbial
characteristics. The potential exposure and toxicity of AgNPs is unknown due to varying
physicochemical particle properties and lack of toxicological data. The aim of this safety
assessment is to derive a provisional tolerable intake (pTI) value for AgNPs released from
blood-contacting medical devices. A literature review of in vivo studies investigating critical
health effects induced from intravenous (i. v.) exposure to AgNPs was evaluated by the
Annapolis Accords principles and Toxicological Data Reliability Assessment Tool (ToxRTool).
The point of departure (POD) was based on an i. v. 28-day repeated AgNP (20 nm) dose
toxicity study reporting an increase in relative spleen weight in rats with a 5% lower confidence
bound of the benchmark dose (BMDL05) of 0.14 mg/kg bw/day. The POD was extrapolated to
humans by a modifying factor of 1,000 to account for intraspecies variability, interspecies

differences and lack of long-term toxicity data. The pTI for long-term i. v. exposure to 20 nm
AgNPs released from blood-contacting medical devices was 0.14 μg/kg bw/day. This pTI may
not be appropriate for nanoparticles of other physicochemical properties or routes of
administration. The methodology is appropriate for deriving pTIs for nanoparticles in general.

Keywords
Silver nanoparticles, Safety assessment, Provisional tolerable intake, Medical devices, Intravenous, Uncertainty
factors, Point of departure, Annapolis accords, ToxRTool

1. Introduction
Nanotechnology has many applications in medical devices; however, knowledge gaps exist inhibiting
assessment of the risk of exposure and toxicity of nanoparticles released from medical devices to
patients (Wijnhoven et al., 2009). Prediction of the toxic effects of nanoparticles could be calculated
from the known toxicity of their bulk materials but is prevented due to fundamental physical and
chemical properties that change as the particle size is decreased within the nanoscale range (Lai and
Sayre, 2009, SCENIHR, 2009). Safety assessment of nanoparticles is further complicated by the vast
number and variety of physicochemical properties produced differing widely by particle size, shape,
agglomeration state, crystal structure, chemical composition, surface area and surface properties (Pang
et al., 2016, Lai and Sayre, 2009, Warheit et al., 2007, Isakovic et al., 2006, Sayes et al., 2006a, Sayes
et al., 2006b, Nemmar et al., 2003). A stringent battery of biological tests for each nanomaterial with
varying physicochemical particle properties on a case-by-case basis would be costly, time-consuming
and impractical (Lai, 2015, Oberdorster et al., 2005).
To address this complex problem, provisional tolerable intake (pTI) values can be determined for
exposure to nanoparticles of specific physicochemical properties, routes of entry and durations of
exposure. A pTI value is a dose estimate of the average daily intake of a chemical over a period of time
based on body mass and is considered to be without appreciable harm to human health
(ANSI/AAMI/ISO 10993-17:2002/(R)2012, 2003). A pTI is normally expressed in milligrams per
kilogram of body mass per day (mg/kg bw/day) and derived as a part of establishment of an allowable
limit for a leachable chemical in a medical device.
Silver nanoparticles (AgNPs) are incorporated into blood-contacting medical devices for their antimicrobial properties, such as in intravascular (i. v.) catheters (Wijnhoven et al., 2009). The toxic effects
induced by AgNPs have been evaluated using in vitro and short-term in vivo studies (Dubey et al., 2015,
Gaillet and Rouanet, 2015, Ge et al., 2014, Wijnhoven et al., 2009); however, the potential exposure and
subsequent toxicity of AgNPs released from medical devices via i. v. exposure to patients is not
completely understood. The aim of this safety assessment is to derive a pTI value for AgNPs released
from blood-contacting medical devices. A comprehensive literature review of in vivo studies
investigating critical health effects induced from i. v. exposure to AgNPs was reviewed
(ANSI/AAMI/ISO 10993-17:2002/(R)2012, 2003) and evaluated by the Annapolis Accords principles
as described by Gray et al. (2008). Key studies were further analyzed by the Toxicological Data
Reliability Assessment Tool (ToxRTool) (Schneider et al., 2009) to determine the critical study for use
in derivation of the pTI.

The point of departure (POD) is the most sensitive critical health effect reported in the critical study
typically presented as a no-adverse-effect-level (NOAEL) or bench mark dose (BMD) value (FDA,
2015). The POD is then extrapolated to humans by a modifying factor (MF) determined based on
scientific review and analysis to account for uncertainties including intraspecies variability, interspecies
differences and lack of long-term toxicity data. The derivation of a pTI dose is similar to the
methodology used in the safety assessment of di(2-ethylhexyl)phthalate (DEHP) (FDA, 2001) released
from PVC medical devices and in Weldon et al. (2016) in the development of an occupational exposure
limit for silver nanoparticles. The pTI derived in this work should be considered provisional because a
limited number of critical toxicological studies are currently available and may not be appropriate for
nanoparticles of other physicochemical properties or routes of AgNP administration. The methodology
used was deemed appropriate for deriving pTIs for nanoparticles in general.

2. Literature review and selection of toxicological studies
2.1. Criteria for selection of toxicological studies
A comprehensive literature search using PubMed, Web of Science and Embase was conducted to
identify in vivo studies investigated the critical health effects after i. v. exposure to AgNP that were
published from August 31, 2006 to August 31, 2016. Studies were evaluated based on principles
outlined in the Annapolis Accords on The Use of Toxicology in Risk Assessment and Decision-Making
(Gray et al., 2008) and are presented in Table 1. Criteria for inclusion or exclusion of a study included:
1) administration route similar to the route of exposure to medical devices containing AgNPs, 2)
relevance of the toxicological effects to human health, 3) clearly established critical health effects
between a biomarker and functional endpoint, so that only studies with effects broadly considered to be
adverse (histopathological or functional changes) would be used for pTI derivation; and 4) high quality
of the published data based on rigor, power, corroboration, universality, proximity, relevance and
cohesion (Gray et al., 2008).
Table 1. Criteria for selection of toxicological studies based on Annapolis Accords principles.a
Principle

Criteria for Inclusion in Derivation of a Provisional Tolerable Intake Value
− Evaluated for proper conduct and analysis.

Rigor

− Greater weight given to more rigorous studies.
− Studies with poor methods discounted.

Power

Corroboration

Universality

− Statistical power of the experimental design examined for ability to detect effects of a given
magnitude.
− For example, some "negative” studies may misinterpret a low level of response as a lack of
response.
− Determine if effects are replicated in similar studies or under varied conditions to predict if
effects would be seen under conditions of human exposure as well.
− Conversely, lack of corroboration of effects provides a basis for doubting either the validity of
single experimental results or their applicability to other species or conditions of exposure.
− Effect seen in multiple species by various routes of exposure gives confidence that the effect
may apply to humans.

Principle

Criteria for Inclusion in Derivation of a Provisional Tolerable Intake Value
− If an effect is restricted to a certain species, strain, or route of administration, there is less
confidence in the ability to generalize the response to other species or routes.

Proximity

− When effects exist in a species taxonomically-related to humans or at exposure doses similar
to those expected in humans, such results weigh more heavily than effects found in
taxonomically less related species by less relevant routes or at markedly different doses.

Relevance

− Knowledge of the underlying biologic basis for toxicity in animals can assist in determining
whether similar metabolism, mechanisms of damage and repair and molecular targets of toxic
action occur in humans. Accordingly, confidence in applicability to humans can increase or
decrease.

Cohesion

− Extent to which all data are consistent and subject to a single, biologically plausible
explanation increases the weight-of-evidence when comparing situations where inconsistencies
require ad hoc explanations and exceptions to general patterns.

aPrinciples outlined as in (Gray et al., 2008).

Studies that met the Annapolis Accords principles were furthered analyzed by the ToxRTool. The
ToxRTool was developed by the European Commission's Joint Research Center in 2009 (Schneider
et al., 2009) and built upon Klimisch categories (Klimisch et al., 1997) to evaluate peer-reviewed
publications providing criteria and guidance for accessing the reliability of toxicological studies. The
methodology of how the tool assesses data reliability from a toxicological study is previously described
in Schneider et al. (2009). For our use, the in vivo spreadsheet of the ToxRTool was used to determine if
21 criteria were met in the following 5 areas: (1) test substance identification, (2) test organism
characterization, (3) study design description, (4) study results documentation and (5) plausibility of
study design and data. To minimize rater bias during analysis and provide a more objective screening
(Segal et al., 2015), three raters were employed to score each study independently while blinded to the
other's ratings. Ratings were jointly reviewed to conclude the score of the study. Studies that are
categorized as reliable (scores of 1 or 2) are deemed appropriate for use in derivation of the pTI.
2.2. Summarization of in-vivo toxicological data
The comprehensive literature review identified eighteen (18) in vivo studies investigating the critical
health effects after i. v. AgNP exposure. These studies are summarized in Table 2 and in more detail in
the Supplemental Material considering study methodology including animal model used,
characterization of AgNPs employed, AgNP treatment dose, exposure and duration, toxicological health
effects seen, POD reported and appropriateness of the study for derivation of the pTI based on the
Annapolis Accords. A study assessed to be lacking in any of the Annapolis Accords criteria does not
mean the study lacked scientific merit, but does reduce its appropriateness for deriving a pTI (Table 1).
Table 2. Summarization of In vivo studies investigating the toxicity and health effects of intravenous
silver nanoparticle exposure.

Species AgNP Treatment Exposure/Durat
(strain,
Dosea
ion
sex)

Toxicological
Health Effect

Point of Departurea

Appropriat Reference
e-ness of
Study for
pTI
Derivationb

Mouse studies
Mouse 5 mg/kg bw/day
(C57BL (20 and 200 nm
6, wild AgNP dispersed
type
in dH2O/10X
(WT)
BSA/10X PBS in
and 8- 8:1:1 ratio)
oxon = 6 per
guanine treatment
DNA
glycosylas
e
knocko
ut (KO)
male)

Single injection
and euthanized
1 and 6 days
after treatment

Genotoxicity: ↑
NOAEL/LOAEL: None
DNA-SB and alkali
sites in KO lung
(200 nm, 7 days).
↑ Fpg-ss lesions in
lung (200 nm, 7
days) and testis of
WT (20 and
200 nm, 7 days)
Gene expression:
↑ Atm, Rad51,
Sod1, Fos and
Mmp3 in KO lung
(200 nm, 1 and 7
days). ↑ Atr and
Rad51 in KO testis
(20 and 200 nm, 7
days).

Lacks
Power

Mouse 0.66 mg/kg bw/d
(CD-1, ay (10 nm AgNP
female) in CT buffer)
n = 8–10
pregnant females
per treatment

3 daily injections
of 2.2 mg/ml on
GDs 7, 8, 9 and
euthanized 1
day after
treatment

Histopath: No
NOAEL/LOAEL: None
abnormalities
Reprod: ↑ number
of smaller-sized
GD10 embryos

Lacks
Austin
Power,
et al.,
Corroborati 2016
on and
Universality

Mouse 1.2 and
(CD-1, 2.2 mg/kg bw/da
female) y (50 nm AgNP in
CT buffer)
n = 6–12
pregnant females
per treatment

3 day
treatments on
GDs 7, 8, 9 and
euthanized 1
day after
treatment

Histopath: No
abnormalities
Reprod: No gross
abnormalities to
embryo

No adverse Austin
effectb
et al.,
2012

Mouse 0.2, 2 and
(Balb/c, 5 mg/kg bw/day
unknow (20 nm AgNP
n
maintained in 4%
gender) polyoxy-ethylene
glycerol trioleate

Single injection
and euthanized
8 h after
treatment

Toxicity: No effect NOAEL:
on body weight
2 mg/kg bw/day
Hepatic: ↑ ER
stress marker
levels
(5 mg/kg bw/day)

NOAEL:
2.2 mg/kg bw/day

Asare
et al.,
2016

Lacks
Chen
Power and et al.,
Universality 2016

Species AgNP Treatment Exposure/Durat
(strain,
Dosea
ion
sex)

and 4% Tween
20)
n = 3 per
treatment

Mouse 0.25 mg/kg bw/d
(Balb/c, ay (10, 75 and
female) 110 nm AgNP in
5% isotonic
glucose solution)
n = 3 per
treatment

Toxicological
Health Effect

Point of Departurea

Appropriat Reference
e-ness of
Study for
pTI
Derivationb

Toxicity: Liver,
NOAEL/LOAEL: None
kidney and lung
had inflammation
(greatest after 75
or 100 nm)

Lacks
Guo et al.,
Power and 2016
Universality

Blood: ↓
lymphocyte
percentage and ↑
IL-6
Histopath:
Thickened alveolar
walls, multifocal
consolidation and
infiltration of focal
inflammatory cells
in lungs.
Disorganized
hepatic cords,
damaged hepatic
lobules, edema
cytoplasm and
ballooning-like
tissue changes in
the liver. No
effects in the brain,
heart, spleen and
kidneys. ↑
apoptotic cells in
the lung, liver,
spleen and kidneys
(5 mg/kg bw/day).
Single injection
and euthanized
4 h or 1, 3, 7
days after
treatment.
3 injections on
days 1, 4 and 10
and euthanized
7 days later

Mouse 1.0 mg/kg bw/da Injections on 0, Toxicity: No effect NOAEL/LOAEL: None
(CD-1, y (14 nm, citrate- 3, 6, 9, and 12 on body weight
male) coated AgNP) in days and
Histopath: ↑

Lacks
Power

Garcia
et al.,
2014

Species AgNP Treatment Exposure/Durat
(strain,
Dosea
ion
sex)

Mouse
(B6C3F
1,
male)

Toxicological
Health Effect

Point of Departurea

PBS
n = 6 per
treatment

euthanized 15,
60, and 120
days

lumen volume and
tubule diameter
and ↓
seminiferous
epithelium volume
density in the testis
(15 and 60 days).
↑ % of apoptotic
germ cells in the
testis. ↑ cytoplasm
and size of Leydig
cells in the testis
(15 and 60 days).
Hormone: No
effect in serum
levels of LH or FSH.
↑ serum and
intratesticular
testosterone at 15
days
Reprod: No effects
on sperm
concentration and
motility (15–20
days)

0.5, 1.0, 2.5, 10,
20 mg/kg bw/day
(5 nm, PVPcoated AgNP)
25 mg/kg bw/day
(15–100 nm,
PVP-coated
AgNP)
25 mg/kg bw/day
(10–80 nm,
silicon-coated
AgNP)
n = 5 per
treatment

Single injection
(5 nm, PVPcoated)
Single injection
and 3 day
repeat dose
(15–100 nm,
PVP-coated and
10–80 nm,
silicon-coated)

Gentox:
NOAEL (5 nm PVPCytotoxicity of
coated):
reticulocytes (PVP- 20 mg/kg bw/day
coated) and
presence of
oxidative damage
(Comet Assay) in
liver (PVP and
silicon-coated
AgNPs). No
increase in
mutation
frequencies in the
Pig-a gene or the

Appropriat Reference
e-ness of
Study for
pTI
Derivationb

Lacks
Li et al.,
Corroborati 2014
on and
Universality

Species AgNP Treatment Exposure/Durat
(strain,
Dosea
ion
sex)

Toxicological
Health Effect

Point of Departurea

Appropriat Reference
e-ness of
Study for
pTI
Derivationb

percent of
micronucleated
(MN) reticulocytes.
Mouse 10 mg/kg bw/day
(CD-1, (10, 40 and
male) 100 nm, CT- or
PVP-coated,
spherical AgNP
suspended in
Milli-Q water)
n = 3 per
treatment

Single injection
and euthanized
1 day after
treatment

Toxicity: 2
mortalities. ↓
body weight, ↑
spleen weight.
Midzonal
hepatocellular
necrosis and gall
bladder
hemorrhage
(10 nm).

Mouse
(ICR,
male
and
female)

Single injection
and euthanized
at 6, 12 h and 1,
7, 14 days

Toxicity: No
NOAEL:120 mg/kg bw No adverse Xue et al.,
significant changes /day
effectc
2012
in body or relative
organs weights
were observed.
Histopath:
Infiltration of focal
inflammatory cells
and thickened
alveolar walls in
the lungs at day 7
but diminished by
day 14
(120 mg/kg bw/day
). Liver edema and
loose interstitial
cytoplasm in
hepatic cells
(120 mg/kg bw/day
). None in brain,
heart, spleen,
kidneys, testicles
or ovaries

7.5, 30, and
120 mg/kg bw/da
y (15 nm AgNP
suspended in
saline)
n = 5 per sex per
treatment

NOAEL/LOAEL: None

Lacks
Recordati
Power and et al.,
Corroborati 2016
on

Species AgNP Treatment Exposure/Durat
(strain,
Dosea
ion
sex)

Mouse 1.0 mg/kg bw/da
(ICR,
y (8 nm, spherical
female) AgNP)
n = 20 per
treatment

Single injection
at 6.5 dpc and
euthanized at
13.5, 15.5 and
17.5 dpc

Toxicological
Health Effect

Point of Departurea

Reprod: ↑
NOAEL/LOAEL: None
progression of
meiotic prophase I
of female fetal
germ cells
Gene expression:
↑ meiosis-specific
genes, Stra8, Daz1,
Scp1, Scp3 and
Dmc1 and ↓
developmentrelated genes,
Cx37, ZP
glycoprotein 1, 2
and 3, and Figla. ↑
imprinted genes,
H19, Zac1, Ascl2,
Snrpn, Kcnq1ot1,
Peg3, Zac1, H19,
Igf2r and Igf2.
DNA methylation:
↓ Zac1 and ↑
Igf2r

Appropriat Reference
e-ness of
Study for
pTI
Derivationb
Lacks
Zhang
Power,
et al.,
Corroborati 2015a
on and
Universality

Rat Studies
Rat
(Wistar
WU,
male
and
female)

0.0082, 0.0025,
0.074, 0.22, 0.67,
2.0 and
6.0 mg/kg bw/da
y (20 and 100 nm
AgNP suspended
in PB)
n = 2–4 per sex
per treatment

Daily injections
for 28 days and
euthanized 1
day after final
treatment

Toxicity: ↓ thymus
and ↑ spleen wt.
Histopath:
enlarged, browncolored spleen,
liver, and lymph
nodes
Immunol: ↓
cytokine
production
including
interferon-γ, IL-10,
and IL-6, as well as
increased serum

BMDL05:
0.14 mg/kg bw/day ↑
relative spleen weight
and
0.001 mg/kg bw/day
for ↓ thymus weight

Chosen as a De Jong
critical
et al.,
study. Used 2013
to derive
the pTI.

Species AgNP Treatment Exposure/Durat
(strain,
Dosea
ion
sex)

Toxicological
Health Effect

Point of Departurea

Appropriat Reference
e-ness of
Study for
pTI
Derivationb

IgM, IgE and
increased blood
neutrophilic
granulocytes
Rat
5 and
(Wistar, 10 mg/kg bw/day
male) (20 nm, spherical
AgNP in NaCl
solution)
5 mg/kg bw/day
(200 nm;
spherical AgNP in
NaCl solution)
n = 7 per
treatment

Single injection
and euthanized
1, 7 and 28 days
after treatment

At
NOAEL:10 mg/kg bw/
10 mg/kg bw/day day (20 nm)
(20 nm)
significantly higher
frequency of
micronuclei after 4
weeks (possible
bone marrow
toxicity)

Lacks
Dobrzynsk
Power,
a et al.,
Rigor,
2014
Corroborati
on and
Universality

Rat
10 mg/kg bw/day
(Spragu (117 nm AgNP
e
dispersed in
Dawley, dH2O)
male) n = 7 per
treatment and
n = 5 for controls

Single injection
and euthanized
2 days after
treatment

Urine: Proteinuria NOAEL/LOAEL: None
Blood: ↑
creatinine and urea
in serum
Nephro:
accumulation of
glycosaminoglycan,
hemorrhage in
renal cortex and ↑
thickness of the
parietal layer in
Bowman's capsule.

Lacks
Feng
Power,
et al.,
Corroborati 2015
on and
Universality

Rat
0.238 mg/kg bw/
(Wistar day (17.3 nm
Kyoto) AgNP dispersed
in H2O
containing 4%
each of PGT and
Tween 20)
n = 3 per
treatment

Single injection
and euthanized
1 day after
treatment

No changes in
NOAEL/LOAEL: None
glutathione, ↑ in
TNF-α, IL-1R1, and
MIP-2 gene
expression (24 h)

Lacks
Gaiser
Power and et al.,
subtle
2013
effects not
considered
critical

Species AgNP Treatment Exposure/Durat
(strain,
Dosea
ion
sex)

Toxicological
Health Effect

Point of Departurea

Appropriat Reference
e-ness of
Study for
pTI
Derivationb

Rat
5 and
(Wistar, 10 mg/kg bw/day
male) (20 nm, spherical
AgNP dispersed
in 0.9% NaCl
solution)
5 mg/kg bw/day
(200 nm,
spherical AgNP
dispersed in 0.9%
NaCl solution)
n = 24 per
treatment

Single injection
and euthanized
1, 7 and 28 days
after treatment

20 nm:Reprod: ↓ NOAEL (200 nm):
sperm count
5.0 mg/kg bw/day
(5 mg/kg bw/day; 1
and 28 days) and
germ count
(5 mg/kg bw/day).
DNA damage in
germ cells (5 and
10 mg/kg bw/day
at 24 h).
200 nm:Morpholog
ical changes in
testes (5 mg/kg
bw/day)

Lacks
Power

Gromadzk
aOstrawska
et al.,
2012

Rat
4, 10, 20 and
(Wistar, 40 mg/kg bw/day
male) AgNP
(13 nm dispersed
in ethylene
glycol)
n = 6 per
treatment

5 day intervals
for 32 days and
euthanized after
treatment

Toxicity: ↓ in body NOAEL:
weight (20 and
10 mg/kg bw/day
40 mg/kg bw/day
after 15 d
exposure). No
effect in organ
weight.
Hematol: ↓
platelet counts and
↑ white blood
cells (20 and
40 mg/kg bw/day)
Hepatotox: ↑ ALT
and AST (20 and
40 mg/kg bw/day)
and ↑ ALP and
GGTP
(40 mg/kg bw/day)
.
Blood: ↑ ROS and
DNA damage.
Histopath: No
inflammation,
damage or
morphological

Lacks
Power

Tiwari
et al.,
2011

Species AgNP Treatment Exposure/Durat
(strain,
Dosea
ion
sex)

Toxicological
Health Effect

Point of Departurea

Appropriat Reference
e-ness of
Study for
pTI
Derivationb

changes in the liver
or kidney.
Rat
(Wistar
WU,
male)

0.0082, 0.0025, Daily injections
0.074, 0.22, 0.67, for 28 days and
2.0 and
euthanized 21
6.0 mg/kg bw/da days after
y AgNP
treatment
(20 nm,CT-coated
dispersed in CT)
n = 5 per
treatment

Toxicity: ↓ body BMD (BMDL05):
and thymus weight 0.98 (0.76)
mg/kg bw/day ↑
and ↑ spleen
spleen wt.
weight and cell
1.3 (0.76)
number.
Immunol: ↑ spleen mg/kg bw/day
monocytes and ↓ ↓ thymus wt.
KLH-specific IgG

Chosen as a Vandebrie
critical
l et al.,
study but 2014
was not
used to
derive the
pTI.

Rat
5, 10 and
Single injection
(Spragu 45 mg/kg bw/day or daily for 3
e
AgNP (7.2 nm,
days
Dawley, spherical) in H2O
male) n = 6 per
treatment and 12
per control

Toxicity: ↓ body LOAEL:
weight
45 mg/kg bw/day
Neurotox/Behavior
al: Locomotor
activity appeared
to be sensitive and
rearing freq. ↓
(45 mg/kg bw/day)

Lacks
Zhang
Power,
et al.,
Corroborati 2013
on and
Universality

Rabbit Studies
Rabbit
(SPF
New
Zealand
White,
male)

0.6 mg/kg bw/da
y AgNP (45 nm in
dH2O and PVP
(<1%))
n = 8 per
treatment

Single injection
with
one euthanized
from each group
at 21, 42, 84 and
105 days and all
euthanized at
126 days

Toxicity: No effect NOAEL/LOAEL: None
on body weight
Histopath: No
effect in testes
Reprod: Lower %
of motile, vigor and
oxygen
consumption of
sperm cells. Sperm
had acrosome and
mitochondrial
damage.

Lacks
Power

Castellini
et al.,
2014

Rabbit
(SPF
New
Zealand
White,
male)

0.5 and
5.0 mg/kg bw/da
y AgNP (7.9 nm,
citrate-coated in
isotonic 5%
glucose solution)

Single injection
with
tissue sampling
at 1, 7 and 28
days

Histopath:
LOAEL:
Pigmentation in
5.0 mg/kg bw/day
liver, increased
inflammatory cell
infiltration levels in
liver, lung and

Lacks
Power

Lee et al.,
2013

Species AgNP Treatment Exposure/Durat
(strain,
Dosea
ion
sex)

n = 4 per
treatment

Toxicological
Health Effect

Point of Departurea

Appropriat Reference
e-ness of
Study for
pTI
Derivationb

kidneys
(5.0 mg/kg bw/day
)

↑: increased; ↓: decreased; ALP: alkaline phosphatase; ALT: alanine transaminase; AST: aspartate
aminotransferase; Atm: Ataxia telangiectasia mutated; BMD: bench-mark dose; BMDL05: BMD 95%
lower confidence limit; BSA: bovine serum albumin; CT: citrate; dH2O: distilled water; Ddb2: damage
specific DNA binding protein 2; dpc: days post conception; DNA-SB: DNA strand breaks; ER:
endoplasmic reticulum; Fpg-ss: Formamidopyrimidine DNA glycosylase sensitive sites; GD: gestational
day; KO: 8-oxoguanine DNA glycosylase knock-out; LOAEL: lowest-observed-adverse-effect-level;
Mmp3: matrix metallopeptidase 3; n: sample size; NaCl: sodium chloride; NOAEL: no-observedadverse-effect level; PB: phosphate buffer; PBS: phosphate buffered saline; PGT: polyoxyethylene
glycerol trioleate; PVP: polyvinylpyrrolidone; ROS: reactive oxygen species; Sod1: superoxide
dismutase 1.
amg/kg bw/day.
bBased on the Annapolis Accords principles (Gray et al., 2008).
cStudy has no adverse effect so can be excluded from further evaluation by the Annapolis Accords principles.

2.3. Identification of the point-of-departure (POD)
Two i. v. 28-day repeated AgNP dose toxicity studies in rats by De Jong et al. (2013) and Vandebriel
et al. (2014) were deemed appropriate key studies for derivation of the pTI value for AgNPs released
from blood-contacting medical devices (Table 2 and Supplemental Material). De Jong et al. (2013)
(Table 3) and Vandebriel et al. (2014) met the principles outlined in the Annapolis Accords (Gray et al.,
2008) (Table 1). The ToxRTool was used to further verify the study quality and reliability of data of
these two studies, and both were assigned a category of reliable with restrictions (score of 2) confirming
their appropriateness for derivation of the pTI. Both studies were of similar experimental design with
minor differences as Vandebriel et al. (2014) was a follow-up study to De Jong et al. (2013). The study
by De Jong et al. (2013) analyzed the toxic effects of repeated 28-day dosing of 20 and 100 nm AgNP
with no recovery period prior to evaluating critical health effects. Vandebriel et al. (2014) analyzed the
toxic effects of repeated 28-day dosing of 20 nm, citrate-coated AgNPs for 28 days with a 28-day
recovery period prior to evaluating critical health effects (Table 2). Both studies report BMDL05, the
lower limit of the 95% confidence interval surrounding the BMD, for multiple toxicological parameters
including body, spleen, thymus and liver weight, blood chemistry, hematology parameters and immune
parameters. The BMDL05 was determined from fitting a dose-response curve to the dataset over the
entire dose range studied (De Jong et al., 2013, Vandebriel et al., 2014).

Table 3. In vivo Critical Study (De Jong et al., 2013) Chosen to Derive the Provisional Tolerable Intake
Value for Intravenous Silver Nanoparticle Exposure Met the Annapolis Accords Criteria.
Principle

Criteria for Inclusion in Derivation of a Tolerable Intake Value
The selected study properly conducted methods and reporting during their analysis of AgNP
toxicity leading to increased confidence:
− Followed OECD Guideline 407, for the testing of chemicals
− Used a wide dose range (0, 0.0082, 0.0025, 0.074, 0.22, 0.67, 2.0, 6.0 mg/kg bw/day) as
opposed to the conventional three dose group exposure design (low, mid and high dose)
− Treated with repeated dose exposures as opposed to a single injection

Rigor

− Use of two different sizes of AgNPs (20 and 100 nm)
− Incorporated both male and female animals
− Provided toxicity data on general (e.g. body and target organ weight change) as well as specific
(immunological) endpoints
− Measured levels of biochemical parameters in blood serum
− Provided histopathological analysis of targeted organs including spleen, thymus, liver, and
lymph nodes
Statistical power of the study was appropriate to have the ability to detect effects of a given
magnitude including:

Power

− Sample size per treatment was small, but the increase in the number of dose groups improved
the characterization of the dose response.
− Provided a robust and adequately conducted statistical analysis for the calculation of the
BMD05 for several parameters

Corroboration Similar effects in immunologically functional tissues were reported in multiple studiesa,b.
Universality

Similar effects are reported in different speciesa.

Proximity

Critical health effects shown in a species taxonomically related to humans such as rodentsa,b.

Relevance

Toxic response in animal models include metabolism, mechanisms of damage and repair, and
molecular targets of toxic action is expected to be the same in humans.

Cohesion

A similar plausible biological explanation is seen across studiesb.

aRecordati et al., 2016.
bVandebriel et al., 2014.

The most sensitive critical health effect reported in the critical study is selected as the POD for
derivation of a pTI value. When multiple critical health effects are reported in the critical study, or
between multiple studies, selection of the POD is based on the lowest POD reported, with the highest
magnitude of response (e.g. percent change or change in standard deviation from the control). The use of
a NOAEL has limitations due to its determination being based on one experimental dose tested,
dependence on doses and dose spacing chosen by the study authors, and the sample size of the animals
per each dose group (Filipsson and Victorin, 2003). More advanced procedures such as benchmark dose
(BMD) analysis can identify a POD value by including dose response data from the entire study, based

on selection of the response level by the investigator (Weldon et al., 2016, EFSA Scientific Committee,
2012, FDA, 2001, Crump, 1984) reducing the variability of the POD to ≤10% from a possible ≥20%
when using a NOAEL (Gaylor and Kodell, 2000). The BMD includes calculation of the variability in the
dose–response data as the 90 or 95% confidence limit of the BMD is calculated and presented as the
BMDL10 or BMDL05, respectively (Weldon et al., 2016).
We applied this critical effect selection concept to De Jong et al. (2013) and Vandebriel et al. (2014).
The critical health effects reported from exposure to 20 nm AgNP by De Jong et al. (2013) was an
increase in spleen weight, BMDL05 of 0.14 mg/kg bw/day (maximal response of +150%) and a decrease
in thymus weight, BMDL05 of 0.001 mg/kg bw/day (maximal response of −17.4%). Vandebriel et al.
(2014) confirmed these findings reporting an increase in spleen weight and a decrease in thymus weight
with a BMDL05 of 0.76 mg/kg bw/day for both endpoints. The BMDL05 of 0.14 mg/kg bw/day for
increased spleen weight reported in De Jong et al. (2013) qualified to serve as the critical study for
derivation of the pTI based on the BMDL05 being the lowest critical health effect with the highest
response. The increased BMDL05 values reported in Vandebriel et al. (2014) may have been due to the
28-day recovery period after the final treatment used in the study; whereas, De Jong et al. (2013) did not
have a recovery period.

3. Derivation of a provisional tolerable intake
3.1. Evaluation of uncertainties
The uncertainty factor (UF) concept is integral to safety assessment to ensure when extrapolating the
POD derived in animal models to human health that the value yields a no-adverse-effect dose for the
greater majority of the human population including sensitive subpopulations (Dankovic et al., 2015).
UFs considered are interindividual variability among the human population (UF1), interspecies
variability in response to exposure when extrapolating data from animal models to humans (UF2) and
lack of chronic toxicity exposure data (UF3) (FDA, 2001). Use of a default of 10 for each UF employed
is standard when data is lacking; however, UFs should be derived on a case-by-case basis ranging from
1 to 10 based on chemical-biological specific adjustment factors when available or with scientificsupport based on data in literature (EFSA Scientific Committee, 2012, Dankovic et al., 2015). The
rationale for assigning uncertainty factors (UF) in the derivation of the provisional pTI in our study was
in accordance to guidelines from the International Organization for Standardization (ANSI/AAMI/ISO
10993–17:2002/(R)2012, 2003).
3.1.1. Interindividual variability in human population (UF1)

An UF1 accounts for interindividual variability among the human population. When data assessing
human variation is lacking, a default of 10 is typically assigned to account for the range of human
variability when the safety assessment has been based on animal studies (ANSI/AAMI/ISO 1099317:2002/(R)2012, 2003). If animal studies suggest that variation among humans may be significant, an
UF1 of or approaching 10 is selected (ANSI/AAMI/ISO 10993-17:2002/(R)2012, 2003). Sex-related
differences were found in a mouse study reporting a significant difference in the elimination of Ag from
blood during the 24 h after i. v. AgNP (15 nm) treatment, with a half-life of 29.9 h in females compared
to 15.6 h in males. Additionally, the lungs and kidneys showed a sex-dependent accumulation of Ag
with higher concentrations in females compared to males (Xue et al., 2012) (Table 4). Other exposure
routes have also found sex-related differences after AgNP exposure. A 28-day oral toxicity study in rats

reported a 2-fold increase in AgNP in female kidneys compared to males with higher accumulation
found in all kidney regions including the cortex, medulla, inner medulla and cortical glomeruli
compared to males (Kim et al., 2008, Kim et al., 2009). A 90-day inhalation study in rats found
statistically significant increases (p < 0.01–0.05) in parameters of lung inflammation in females
compared to males (Sung et al., 2008). Additionally, interindividual differences in the excretion of Ag in
urine and feces between rats have been reported after exposure with 20 and 200 nm AgNP
(Dziendzikowska et al., 2012). These animal model studies suggest that sex-related and interindividual
differences in AgNP toxicokinetics may exist in humans. Due to the lack of i. v. studies characterizing
individual variability in humans and animal model data indicating the potential for interindividual
variability between sexes, a default UF1 of 10 was assigned.
Table 4. Pharmacokinetic or Biodistribution Studies of Intravenous Exposure to 20 ± 5 nm Silver
Nanoparticles.
Species
(strain,
sex)

AgNP Treatmenta

Duration

Tissue Distribution and
Excretionb

Mouse
(BALB/c,
male and
female)

1.3 mg/kg bw/day (25 nm,
PVP-coated AgNP spheres
suspended in PBS)
Injected 2x a week for 28
days
n = 3–5 per treatment

15, 39 and
78 days
(females)
120 days
(males)

Mouse
(ICR, male
and
female)

120 mg/kg bw/day (15 nm
AgNP dispersed in saline)
Single injection
n = 6 per sex per treatment

10, 20,
Sp > Li > Lu > Ki (females had
30 min; 1, 3, higher silver levels in the Lu and
6, 12 h; 1, 7, Ki than males)
14 days

Rat
(Wistar,
male)

Rat
(Wistar,
male)

Halflife

Sp > Li > Ki » Lu > H
NR
(females, levels ↓ over time)
Te > Sp > Li » Ki > H > Ln > M (120
days)

Reference

Wang et al.,
2013

NR

Xue et al., 2012

5 mg/kg bw/day (20 nm,
1, 7, 28 days Li » Sp > Ki > Lu > Br (1 day)
spherical AgNP dispersed in
Lu > Li > Sp > Ki > Br (7 days)
Ki » Li > Sp > Lu > Br (28 days)
NaCl solution)
Single injection
n = 8 per treatment

NR

Dziendzikowska
et al., 2012

0.0238–
0.0276 mg/kg bw/day
(20 nm, spherical AgNP
dispersed in PB)
Single injection and 5-day
repeat treatment
n = 3 per treatment

NRc Lankveld et al.,
2010

2, 3, 5, 6, 8, Li » Ki > Te > Sp > Lu > Br > H
11 and 17
(single injection; Day 2)
day
Li » Ki > Te > Sp > Lu > Br > H
(5-day repeat treatment; Day 6)
Li » Ki > Sp > Te > Br > Lu, H (5day repeat treatment; Day 17)

NaCl: sodium chloride; NR: Not reported; PB: phosphate buffer; PBS: phosphate buffered saline; PVP:
polyvinylpyrrolidone.
aSize (nm) and/or coating of particles, number of treatments and concentration (mg/kg bw/day).

bBr, brain; Fe, feces; H, heart; K, kidneys; Li, liver; Ln, lungs; M, muscle; Se, serum; Sp, spleen; Te, testis; Th,
thymus; Ur, urine.
cAccumulation of AgNP occurred in all organs with most in kidneys (factor 5.5), liver (factor 5) and brain (factor
4).
3.1.2. Interspecies variability (UF2)

UF2 accounts for uncertainty in extrapolating data from animal models to humans (ANSI/AAMI/ISO
10993-17:2002/(R)2012, 2003). Traditionally, a default of 10 has been applied to account for inherent
differences between animals and humans, who may be more sensitive to chemical critical health effects
(Lehman and Fitzhugh, 1954). If the toxicity and toxicokinetics are known and similar between animals
and humans, a smaller uncertainty factor may be used with justification (ANSI/AAMI/ISO 1099317:2002/(R)2012, 2003). There is currently limited data on the pharmacokinetics, pharmacodynamics
and toxicity mechanisms of AgNP to evaluate the relevance of animal data for human responses (Lin
et al., 2015, Sweeney et al., 2015, Bachler et al., 2013, Lankveld et al., 2010, Faustman, 1996). The
pharmacokinetic and biodistribution studies available do not report the half-life of AgNPs after i. v.
exposure to 20 ± 5 nm AgNPs (Table 4). Studies in smaller AgNPs by Park et al. (2011) and Lee et al.
(2013) report the half-life of AgNPs (7.9 nm, citrate coated) is species-dependent with 4.1 days in rats
and 11.7–16.3 days in rabbits, respectively, after injection. The half-life was approximately 3–4 fold
higher in rabbits compared to rats. This increase in half-life for the larger mammal is consistent with a
lower metabolic rate and longer circulation time allowing for development of a more stable NP protein
corona before distribution to tissue or elimination from the body (Sahneh et al., 2015, Riviere, 2013).
The NP protein corona is a collection of selectively adsorbed biomolecules as the NP comes into contact
with complex biological fluids lowering surface energy, promoting dispersion and defining the
biological interaction of the NP (Monopoli et al., 2012). The formation of the protein corona decreases
the extracellular dissolution of AgNPs into ionic Ag leading to the cellular uptake of the particles
(Shannahan et al., 2015). Additionally, the binding of opsonins could induce a rapid clearance of NP
from the vascular system or the binding of a polyethyleneglycol coating can decrease the uptake by
macrophage cells (Pozzi et al., 2014).
Additionally, studies indicate that human male germ cells exhibit a lower capacity to repair some types
of DNA oxidative lesions including 8-oxo-7,8-dihydroguanine (although 8-oxoguanine-DNA
glycosylase-1 (hOGG1) was present) and showed poor removal of formamidopyrimidine-DNA
glycosylase (Fpg)-sensitive lesions in general, which was not seen in rat male germ cells (Olsen et al.,
2003). Asare et al. (2016) reported that injection of 5 mg/kg bw/day 200 nm AgNPs into hOGG1
knockout mice (proposed as an appropriate model for humans) induced DNA single stranded breaks,
oxidative DNA lesions including Fpg-sensitive lesions and key DNA damage response and repair genes,
Atm, Rad51, Sod1, Fos and Mmp3, in the lung and testis.
These interspecies differences potentially cause extrapolation from animal models to humans to be
difficult (Sahneh et al., 2015). An UF2 was assigned a 10 to account for the interspecies differences
between rodents and humans after exposure to AgNPs.

3.1.3. Route-to-route extrapolation (UF3)

A UF3 accounts for the quality and relevance of the study data and can range from 1 to 100 considering
but not limited to the study having only LOAEL data instead of NOAEL or BMD data; absence of
supporting studies; inappropriate route of exposure; and lack of chronic study data (ANSI/AAMI/ISO
10993-17:2002/(R)2012, 2003). In our literature review, no chronic studies were found for i. v. exposure
to AgNP. A TI that is protective of critical health effects resulting from chronic exposure should be
based on long-term repeated dosing (30–90 days) or a chronic dosing study (90 days–2 years) (U.S.
EPA, 1996, OECD, 1995). A value of 3–10 is typically assigned to account for the possibility of
identifying a lower POD for chronic toxicity when extrapolating from a subchronic animal study.
Assessing the appropriate value is commonly determined by evaluating if the critical effect that is the
basis of the POD could be expected to increase in incidence, severity or occur at a lower dose given
longer exposure time (Dankovic et al., 2015). Following i. v. injection, one of the primary sites of 20 nm
AgNP accumulation has been consistently demonstrated to be in the spleen (Table 4). The localization
of particles within the spleen can be accounted for by their uptake by the abundant number of resident
macrophage populations (Lankveld et al., 2010). The marginal zone and red pulp macrophages are the
major particle scavengers in the spleen followed by the peritoneal macrophages and dendritic cells
(Recordati et al., 2016, Xue et al., 2012). Phagocytosis of AgNPs stimulates inflammatory signals
through the generation of reactive oxygen species in macrophage cells (Martinez-Gutierrez et al., 2012,
Park et al., 2010a, Park et al., 2011). In vitro studies indicate AgNP induces oxidative stress resulting in
endoplasmic reticulum stress (Chen et al., 2016) and apoptosis in spleen cells (Xue et al., 2012,
Lankveld et al., 2010).
Additionally, De Jong et al. (2013) examined the organ weight and histology of the testes and brain,
which have been shown to be sensitive health effect endpoints, but reported no effects. AgNPs can cross
the blood-testis and blood-brain barrier accumulating over time in these organs (Zhang et al., 2015a,
Wang et al., 2013, Lee et al., 2013, Dziendzikowska et al., 2012, van der Zande et al., 2012, Lankveld
et al., 2010, Sharma et al., 2010, Kim et al., 2009). In vivo i. v. studies in multiple species report testes
toxicity after short-term AgNP treatment (Table 2) (Asare et al., 2016, Gromadzka-Ostrowska et al.,
2012, Castellini et al., 2014). AgNP-induced toxicity in on the male reproductive system and
spermatozoa was seen after other routes of exposure (Lafuente et al., 2016, Zhang et al., 2015a, Sleiman
et al., 2013, Miresmaeili et al., 2013, Kim et al., 2009). Adverse effects induced by AgNPs in the brain
has been reported including neurotoxicity (Bagheri-Abassi et al., 2015, Shanker Sharma and Sharma,
2012, Sharma et al., 2010, Tang et al., 2009). To account for the possibility that the critical study might
have not examined the most sensitive health effect endpoint, a UF3 of 10 was assigned.
3.2. Calculation of the tolerable intake
A modifying factor (MF) of 1,000, which is the mathematical product of the three UFs
(UF1·UF2·UF3 = MF), was applied to account for uncertainties including intraspecies variability
(UF1 = 10), interspecies differences (UF2 = 10) and lack of chronic toxicity data (UF3 = 10). The pTI for
long-term i. v. exposure to 20 nm, uncoated AgNPs was determined to be 0.14 μg/kg bw/day derived
from the POD of 0.14 mg/kg bw/day for immunotoxicological effects as calculated below:

4. Discussion
In this safety assessment, a pTI value was derived for i. v. exposure to 20 nm AgNP. The critical health
effect study appropriate for deriving the pTI was determined to be an i. v. 28-day repeated-dose toxicity
study in rats performed by De Jong et al. (2013) who investigated the immunotoxicological effects of
AgNP. The POD was based on the critical health effect of increased relative spleen weight in rats with a
BMDL05 of 0.14 mg/kg bw/day. Histological analysis of the spleen revealed inflammation and a
brownish pigment in the red pulp indicative of red blood cell degradation, as well as, a decrease in NK
lymphocyte activity, as notable immunotoxic effects (De Jong et al., 2013). T, B and NK cell
populations were increased in the spleen after treatment with 20 nm AgNP, and the authors suggest this
increase in cell number may be responsible for the increase in spleen weight (De Jong et al., 2013). Such
effects may be in part due to the preferential accumulation of AgNP in the spleen. In vitro studies
investigating the toxicity of AgNP in spleen cells report AgNP induces oxidative stress of the
endoplasmic reticulum (Chen et al., 2016) and apoptosis (Xue et al., 2012, Lankveld et al., 2010).
Supporting studies report toxic effects in the testes and sperm, which are considered more sensitive
health effects compared to increase in spleen weight because this effect occurs at lower treatment doses
than what was reported in the critical study by De Jong et al. (2013). De Jong et al. (2013) found no
changes in testes weight or histology after 6.0 mg/kg bw/day AgNP (20 nm) 28-day repeated i. v.
exposure in rats. In contrast, Gromadzka-Ostrawska et al. (2012) reported decreased sperm and germ
count and DNA damage in germ cells after i. v. exposure to 5 mg/kg bw/day AgNP (20 nm); however,
Asare et al. (2016) reported a single i. v. injection of 5 mg/kg bw/day AgNPs (20 nm) did not
significantly increase single strand breaks in the testis 7 days after treatment in mice (Table 2). Castellini
et al. (2014) investigated the toxic effects of a single i. v. injection of 0.6 mg/kg bw AgNPs (45 nm) on
the sperm quality of rabbits throughout a 126-day study reporting sperm cells with a lower percent of
motility, vigor and oxygen consumption and acrosome and mitochondrial damage (Table 2). AgNPs
were seen in the spermatids and ejaculated sperm; however, no effect was seen morphologically in the
testes nor was libido, serum testosterone, sperm concentration or semen volume affected (Castellini
et al., 2014). Although these supporting studies did not meet the Annapolis Accords criteria and not used
to derive the pTI; the scientific merit of these studies were used in determining the level of uncertainty
in deriving the pTI.
Other routes of exposure, albeit at higher doses, collaborate with the observed toxic effects induced in
the testes and sperm after i. v. AgNP exposure. Miresmaeili et al. (2013) reported oral gavage exposure
to AgNP (70 nm) for 48 days induced a dose-dependent decrease in the number of primary
spermatocytes, spermatids and spermatozoa with a NOAEL of 25 mg/kg bw/day and a LOAEL of
50 mg/kg bw/day. Lafuente et al. (2016) investigated the subchronic toxic effects of polyvinyl
pyrrolidone (PVP)-coated AgNPs (average particle core size of 25 nm) by oral gavage on epididymal
sperm rat parameters and found sperm morphology abnormalities after 90 days of repeated dose
treatment with 100 mg/kg bw/day PVP-AgNP. Based on the NOAEL (25 mg/kg bw day) and LOAEL
(100 mg/kg bw/day) reported in Miresmaeili et al. (2013) and Lafuente et al. (2016), respectively, and a
BAForal of 4% to account for oral bioavailability (Bachler et al., 2013, Loeschner et al., 2011, Kim et al.,
2010), the estimated i. v. NOAEL is calculated to be ranging from 1.0 to 4.0 mg/kg bw/day. Abdominal
subcutaneous injection of AgNP (15 nm) in five doses over 13 days in mice induced reduction of the
average testis weight (5 mg/kg bw/day; postnatal day PND42); reduction in the diameter of the
convoluted tubules (1 and 5 mg/kg bw/day; PND28 and PND42); increase in the rate of abnormal sperm

(5 mg/kg bw/day; PND42 and PND63) and decreased sperm concentration (5 mg/kg bw/day; PND100)
(Zhang et al., 2015b). Furthermore AgNPs are known to accumulate in the testes (Wang et al., 2013,
Lankveld et al., 2010) (Table 4). These testicular toxicity data observed at lower i. v. equivalent AgNP
doses as compared to De Jong et al. (2013) suggests that immunotoxicity of the spleen may not be the
most sensitive toxicological endpoint. To account for the uncertainty that the POD may have not been
the most sensitive critical health effect, a default value of 10 was used for UF3. Use of default values for
UF1, UF2, and UF3 results in a conservative MF of 1,000 to be applied to the POD pTI of
0.14 μg/kg bw/day. This threshold dose represents acceptable exposure for non-cancer health effects
resulting from particles leached from medical devices containing 20 nm, uncoated AgNP.
At the time of writing this paper, no patient exposure studies are known investigating AgNPs
released/leached from medical devices. Roe et al. (2008) examined the toxic risk of catheters coated
with 3–18 nm AgNPs in vitro and in vivo. In vitro studies examined Ag release from radioactive Agcoated catheters (600 and 1000 μg/g) placed in saline solution over a period of 10 days. Ag released
from the catheters was relatively constant with an average release of 45.1 ± 1.1 ng/cm for catheters
coated with 1,000 μg/g Ag and 24.1 ± 2.4 ng/cm for catheters coated with 600 μg/g Ag. The release of
Ag was higher on the first day than on the final day of the study, thereby resulting in a biphasic release
of Ag over the time period. Biofilm inhibition and measurement of bactericidal activity was tested on
600 μg Ag-coated catheters in growth medium for 24, 48 or 72 h. The catheters demonstrated significant
antimicrobial activity against all tested microorganism inhibiting cell growth and biofilm formation for
72 h. In vivo studies investigated the toxicity and biodistribution of Ag from radioactive Ag-coated
catheters implanted in the dorsum of C57BI/6J mice and monitored for 10 days. Body weight decreased
by 8% post treatment, but organ weight was unaffected. No other toxicity was reported. Ag excretion
was higher in feces compared to urine with the highest fecal (4.50 ± 0.40 μg) amount on day 2
(approximately 2.1% of implanted Ag) with a decline and plateau of Ag concentration in feces (0.6–
1.0 μg/day) by day 6. Silver urine excretion was low (0.02 μg/day) and accounted for 0.1% of the Ag
implanted. Cumulative excretion of Ag in feces and urine over a 10 day period was 18.33 ± 0.99 μg and
0.22 ± 0.04 μg. By day 10, approximately 84% of Ag remained attached to the catheters with an Ag
recovery rate at 96% on average. The 4% of unaccounted for Ag was reported by authors to be at the
implantation site or along the borders of the insertion pockets where the catheter was inserted (Roe
et al., 2008).
Using the AgNP catheter release information from Roe et al. (2008), a hypothetical patient exposure
situation can be formulated. Assuming 25 μg AgNPs was released daily for 10 days (250 μg
cumulative), this equates to 25% of AgNPs released from a catheter coated with 1,000 μg Ag/g of device
weight. For a 70 kg patient (25 μg/day • 1 day/70 kg patient) (ANSI/AAMI/ISO 1099317:2002/(R)2012, 2003), the patient exposure per day from release of AgNPs from a catheter is
calculated to be 0.357 μg/kg bw/day. The resulting hypothetical exposure value is 2 fold higher than our
pTI of 0.14 μg/kg bw/day with a toxicological risk that is equivocal.
Our pTI value for i. v. exposure to 20 nm AgNPs released from medical devices for i. v. applications can
be compared to other risk assessment values. Weldon et al. (2016) derived an occupational exposure
limit (OEL) of 0.19 μg/m3 for AgNPs from BMDs from subchronic rat inhalation toxicity assessments
with the liver identified as the critical target organ. This OEL can be calculated for a 70 kg adult with an
adult air consumption of 20 m3/day to be 0.05 μg/kg bw/day, which is 2.8 fold lower than the pTI
calculated for long-term i. v. exposure to 20 nM AgNP. A Tolerable Daily Intake (TDI) value for oral

exposure to AgNP based on noncancer effects was reported by Hadrup and Lam (2014) to be
2.5 μg/kg bw/day. When a 4% value for oral bioavailability (4% BAForal) is taken into account, the
health-based exposure limit equals to 0.1 μg/kg bw/day (Bachler et al., 2013, Loeschner et al., 2011,
Kim et al., 2010). This TDI was based on a study by Park et al. (2010b) that reported a NOAEL of
0.25 mg/kg bw/day in mice after daily oral exposure to AgNP (42 nm) for 28 days in both males and
females and consideration of a UF of 100 based on Nielsen et al. (2008) (Hadrup and Lam, 2014). Our
pTI for i. v. exposure to 20 nm AgNPs released from medical devices is similar to the calculated TDI for
oral exposure accounting for 4% BAForal.

5. Conclusion
In summary, this safety assessment derived a pTI value for i. v. exposure to 20 nm AgNPs released from
blood-contacting medical devices. Criteria for selecting relevant studies to determine a benchmark dose
was based on the principles from the Annapolis Accords and ToxRTool analysis. The De Jong et al.
(2013) study, a 28-day study in rats investigating a series of immunotoxicological endpoints after
exposure to 20 nm AgNP, qualified to serve as the critical study for the pTI derivation. De Jong et al.
(2013) reported the lowest dose-dependent critical health effect, which was a BMDL05 of
0.14 mg/kg bw/day for increased spleen weight. To derive the pTI, a modifying factor (MF) of 1,000
was applied to the POD to account for interindividual variability (10), potential interspecies difference
in potency (10), and the lack of chronic toxicity study data (10) based on scientific review.
The pTI for long-term i. v. exposure to 20 nm AgNPs is the first non-cancer risk assessment performed
for the i. v. exposure of AgNP-containing medical devices. This pTI is not necessarily protective for
other sizes or coatings of AgNPs or other administration routes of exposure. The pTI may be used to
complete a safety assessment once data is available to estimate the dose of AgNP that patients are
exposed to following release from blood-contacting medical devices. The approach will enable
toxicological risk assessors to further develop a general index of acceptable toxicological risk with
regard to patient i. v. exposure to AgNP released from medical devices as additional toxicological data
becomes available.
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